![Immuno-Oncology-co-therapies Immuno-Oncology-co-therapies](https://icon.widen.net/content/n7mbz37xun/web/Immuno-Oncology-co-therapies.jpg)
AMCP 2024
In recent years, the number of prescriptions requiring prior authorisation (PA) has continued to grow at a significant rate. Pharmacy prescription rejections for PA may result in the delay of therapeutic treatment, which may also disproportionately impact certain patient populations when looking at select social determinants of health.
We recently presented a poster at the AMCP Conference in New Orleans which discussed quantifying the impact of social determinants of health on patient treatment and disease management within the diabetes market.
![14202 - 011 Blog - SDoH_1440x750 – 2 14202 - 011 Blog - SDoH_1440x750 – 2](https://icon.widen.net/content/pmpbcyxivf/web/14202%20-%20011%20Blog%20-%20SDoH_1440x750%20%E2%80%93%202.jpg)
PMSA 2024
Up to 80% of health outcomes are directly associated with social and environmental factors. Read the latest research from Symphony Health, an ICONplc company; and Healthwise Data on evaluating how aspects of Social Determinants of Health (SDOH) impact patients’ persistence to prescribed diabetic treatments through a driver’s analysis using unsupervised machine learning.
ISPOR
![Diabesity_obesity_diabetes_blog thumbnail Diabesity_obesity_diabetes_blog thumbnail](https://icon.widen.net/content/x0odjcoqiw/web/Diabesity_obesity_diabetes_blog%20thumbnail.jpg)
#1
Read the latest research from Symphony Health, an ICONplc company, on a study that assesses the adherence and discontinuation of GLP-1 receptor agonists and SGLT-2 inhibitors among adult patients with T2D in the United States based on real-world claims and linked clinical data from ICON’s Symphony Health Integrated Dataverse (IDV®).
![vaccine-syringe vaccine-syringe](https://icon.widen.net/content/paalttb4eh/web/vaccine-syringe.jpg)
#2
Since the first approval of recombinant human growth hormone (HGH) in 1987, HGH has been the mainstay of treatment for patients diagnosed with growth hormone deficiency (GHD), Prader-Willi syndrome, Turner syndrome, and others. Read the latest research from Symphony Health, an ICONplc company; on evaluating the impact of HGH drug shortages on patient treatment switching patterns using real-world data.
![blood_cells_002 blood_cells_002](https://icon.widen.net/content/nqctdkjpaq/web/blood_cells_002.png)
#3
Myelofibrosis (MF) is a rare type of hematologic malignancy that affects healthy blood cell production and causes progressive fibrosis in the bone marrow Read the latest research from Symphony Health, an ICONplc company; on evaluating the impact of anemia and blood transfusions on patient treatment selection and survival rates for patients with Myelofibrosis (MF) using real-world data
Get all posters
Download all posters from AMCP 2024, OMSA 2024 and ISPOR.
In this section
- Asset Development Consulting
-
Blended Solutions
-
Cardiac Safety Solutions
-
Clinical & Scientific Operations
- Biostatistics
-
Case studies
- Clinical Operations
-
Clinical Supplies Management
- COVID-19
- Clinical data science
-
Endpoint Adjudication Services
- Global Logistics
- Interactive Response Technology
- Investigator Payments
-
Medical Affairs
-
Medical Call Centre Services
-
Medical Writing & Publishing
- Pharmacovigilance
-
Project and Program Management
-
Site Identification and Feasibility
- Commercial Positioning
- Decentralised Clinical Trials
- Early Clinical
- Language Services
-
Laboratories
- Medical Imaging
- Outcome Measures
- Real World Intelligence
- Regulatory Affairs
- Symphony Health data
- Site & Patient Solutions
- Strategic Solutions
-
Technologies